Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers.

Abstract	In a double-blind, placebo-controlled study, self-administered intranasal human interferon alpha A produced by recombinant DNA technology was given both before and after virus challenge with a respiratory coronavirus. The incidence of colds, the severity of symptoms and signs, and virus replication were all reduced in subjects receiving interferon as compared with those given placebo.
Authors	P G Higgins, R J Phillpotts, G M Scott, J Wallace, L L Bernhardt, D A Tyrrell
Journal	Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 24 Issue 5 Pg. 713-5 (Nov 1983) ISSN: 0066-4804 [Print] United States
PMID	6318655 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
Chemical References	Interferon Type I
Topics	Administration, Intranasal Adolescent Adult Coronaviridae Infections (prevention & control) Humans Interferon Type I (administration & dosage) Middle Aged Respiratory Tract Infections (microbiology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!